OncoMatch

OncoMatch/Clinical Trials/NCT06878248

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer

Is NCT06878248 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Two Component Product CLBR001 + ABBV-461 for breast cancer metastatic.

Phase 1RecruitingCalibr, a division of Scripps ResearchNCT06878248Data as of May 2026

Treatment: Two Component Product CLBR001 + ABBV-461The goal of this clinical trial is to evaluate CLBR001 and ABBV-461 as a treatment for patients with locally advanced or metastatic breast cancer. The goals are to establish the safety and efficacy of the combination therapy while establishing the optimal biologic doses. Patients will be administered a single infusion of CLBR001 cells followed by cycles of ABBV-461 with regular assessments of safety and disease response to treatment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Tumor Agnostic

Triple-Negative Breast Cancer

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: standard of care therapy

Exhaused all standard of care therapy options

Cannot have received: allogeneic stem cell transplant

Prior allogeneic stem cell transplant

Cannot have received: lentiviral- or retroviral-based therapy including CAR-T cell therapy

Prior lentiviral- or retroviral-based therapy including CAR-T cell therapy

Cannot have received: lymphodepleting or T-cell cytotoxic therapy

Prior lymphodepleting or T-cell cytotoxic therapy within 3 months of enrollment

Lab requirements

Blood counts

Kidney function

Liver function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Augusta University Medical Center · Augusta, Georgia
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
  • Roswell Park Cancer Institute · Buffalo, New York
  • University of Virginia · Charlottesville, Virginia
  • Fred Hutchinson Cancer Center · Seattle, Washington

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify